Sign in to continue:

Wednesday, April 8th, 2026

Grown Rogue International Inc. 2025 Annual Report: Company Overview, Business History, and Financial Highlights




Grown Rogue International Inc. – 2025 Annual Report: Key Takeaways for Investors

Grown Rogue International Inc. – 2025 Annual Report: Key Insights for Investors

Overview

Grown Rogue International Inc. has published its Annual Report for the fiscal year ended December 31, 2025. The company, headquartered in Medford, Oregon, is primarily engaged in agricultural production with a focus on cannabis cultivation, processing, and distribution. Over the years, Grown Rogue has evolved from a mining and energy business to a prominent player in the cannabis sector.

Key Highlights and Developments

  • Corporate Structure and History:
    The company was originally incorporated as Bonanza Red Lake Explorations Inc. in 1978. It pivoted to cannabis operations in 2016 and has since undergone several name changes and acquisitions, reflecting its dynamic growth strategy.
  • Share Structure and Outstanding Shares:
    As of April 7, 2026, Grown Rogue had 249,938,980 Subordinate Voting Shares outstanding and zero Multiple Voting Shares. The company’s public float (shares held by non-affiliates) was valued at approximately \$84.99 million as of June 30, 2025, based on OTCQB Venture Market prices.
  • SEC Reporting Status:
    The company is not a well-known seasoned issuer but is a non-accelerated filer, a smaller reporting company, and an emerging growth company. It has complied with all required filings under the Exchange Act and submitted all necessary interactive data files.
  • Recent Acquisitions and Strategic Transactions:

    • Acquisition of 43.48% of Grown Rogue West New York LLC
    • Acquisition of 70% of Abco Garden State LLC
    • Buyout of Canopy Management LLC and Canopy Management’s 20% interest in Golden Harvests LLC
    • Roll-off of Noncontrolling Interest in GR Michigan LLC

    These transactions are significant, as they increase Grown Rogue’s control and revenue participation in key operating subsidiaries, which may positively impact future earnings.

  • Financial Position and Debt Instruments:

    • The company has issued multiple tranches of convertible debentures, including those with original principal amounts of \$1 million, \$2 million, and \$5 million at a 9% interest rate.
    • There are entries related to the settlement and conversion of convertible debentures and warrants, as well as the issuance and settlement of restricted share units and stock options.

    These actions may influence both dilution and capital structure, which are important for current and prospective shareholders to monitor.

  • Regulatory and Legal Position:

    • There is no indication that the company is a shell company.
    • The company has not filed a report on management’s assessment of internal controls under Section 404(b) of Sarbanes-Oxley, but this is typical for smaller reporting companies.
  • Risk Factors:
    The report contains a detailed risk section (Item 1A), which should be reviewed by all investors. The company operates in a highly regulated and competitive industry and is subject to changes in cannabis laws, market dynamics, and regulatory scrutiny.
  • Forward-Looking Statements:
    The company includes standard cautionary statements regarding forward-looking projections. Investors should be aware that actual results may differ materially from those projected due to industry risks and uncertainties.

Potential Share Price Sensitivities

  • Expansion through Acquisitions: The acquisition of additional equity in operating entities and buyouts of minority interests can lead to increased revenues and earnings, potentially enhancing shareholder value.
  • Share Dilution Risk: The settlement of convertible debentures and warrants, as well as the issuance of restricted share units and stock options, may result in further share dilution. Investors should monitor future filings for details on actual dilution and its impact on EPS.
  • Emerging Growth Company Status: This status allows the company to take advantage of certain reduced reporting requirements, but may also mean less transparency compared to larger, more established issuers.
  • Regulatory Environment: As cannabis remains a regulated industry, any significant legislative changes or enforcement actions at the state or federal level could materially affect Grown Rogue’s operations and valuation.

Other Information for Shareholders

  • Corporate Governance: The company’s annual report includes comprehensive sections on executive compensation, related party transactions, and corporate governance, which shareholders are encouraged to review.
  • Market Data and Trading: The Subordinate Voting Shares are not listed on a national securities exchange but are traded on the OTCQB Venture Market.
  • Legal Proceedings: Investors should review the Legal Proceedings section for any ongoing or potential litigation risks.
  • Cybersecurity: The company addresses cybersecurity in its disclosures, reflecting the increasing importance of this risk for public companies.

Conclusion

Grown Rogue International’s 2025 Annual Report reflects a period of active corporate development, expansion through acquisitions, and ongoing capital market activity. The company’s strategy to consolidate control in its subsidiaries may be value-accretive, but investors should remain mindful of dilution risks and the regulatory landscape. The evolving nature of the cannabis industry means that news regarding acquisitions, debt settlements, or regulatory changes could materially move the share price. Investors are strongly advised to review the full risk factors and monitor future filings.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should undertake their own due diligence and consult with a qualified financial advisor before making any investment decisions. The cannabis industry is subject to significant risks and regulatory uncertainties.




View Grown Rogue International Inc. Historical chart here



Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring

Theravance Biopharma, Inc. (TBPH) 2025 Annual Report – Key I...

BayCom Corp 2025 Annual Report: Financial Results, Risk Factors, and Corporate Information

Key Points from the Report BayCom Corp’s Common Stock (no...

   Ad